EcoDrugPlus

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSSCAG00000007313
Gene Symbol: PTPN11
1 Cross references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSSCAG00000009047
Gene Symbol: PTPRB
3 Cross references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Purinergic Receptor P2x 3

Ensembl ID : ENSSCAG00000008526
Gene Symbol: P2RX3
1 Cross references
270 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Purinergic Receptor P2y1

Ensembl ID : ENSSCAG00000008798
Gene Symbol: P2RY1
3 Cross references
190 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Purinergic Receptor P2y12

Ensembl ID : ENSSCAG00000008717
Gene Symbol: P2RY12
3 Cross references
180 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Purinergic Receptor P2y2

Ensembl ID : ENSSCAG00000000139
Gene Symbol: P2RY2
3 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSSCAG00000000825
Gene Symbol: P2RY4
3 Cross references
165 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSSCAG00000000126
Gene Symbol: P2RY6
3 Cross references
182 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Receptor Activity Modifying Protein 1

Ensembl ID : ENSSCAG00000008799
Gene Symbol: RAMP1
3 Cross references
253 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSSCAG00000002077
Gene Symbol: RIPK1
3 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSSCAG00000012870
Gene Symbol: RPTOR
3 Cross references
213 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ret Proto-Oncogene

Ensembl ID : ENSSCAG00000002946
Gene Symbol: RET
3 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).